REGENERON PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
REGENERON PHARMACEUTICALS, INC. (REGN) reported Share-based Payment Arrangement, Expense of $40.77 million for the 9-month period ending 2011-09-30, per its 10-Q filed 2011-10-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2011-10-27
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2011-09-30 was $13.38M, a 52.25% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2010-12-31 was $13.57M, a 56.71% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2010-09-30 was $8.79M, a 17.08% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2009-12-31 was $8.66M.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2010 was $39.90M, a 27.63% increase from fiscal 2009.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2009 was $31.26M, a 3.89% decline from fiscal 2008.
- REGENERON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2008 was $32.52M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2011-09-30 | $13.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $40.77M 10-Q · filed 2011-10-27 | ||
| 2011-06-30 | $27.39M 10-Q · filed 2011-07-28 | |||
| 2010-12-31 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17 | $22.36M derived: sum of 2 quarters · filed 2011-10-27 | $39.90M 10-K · filed 2011-02-17 | |
| 2010-09-30 | $8.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $26.33M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $17.54M 10-Q · filed 2011-07-28 | |||
| 2009-12-31 | $8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17 | $16.16M derived: sum of 2 quarters · filed 2011-02-17 | $31.26M 10-K · filed 2011-02-17 | |
| 2009-09-30 | $7.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $22.60M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $15.09M 10-Q · filed 2010-07-28 | |||
| 2008-12-31 | $32.52M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |